Bristol-Myers Squibb at Bank of America Merrill Lynch Health Care Conference

1. Bank of America Merrill Lynch
Health Care Conference
Doug Manion
Senior Vice President,
Virology, Neuroscience and Japan
May 17, 2012
1

2. Forward-Looking Information
During this meeting, we will make statements about the
Company’s future plans and prospects that constitute forward-
looking statements for purposes of the safe harbor provisions
under the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated as a
result of various important factors, including those discussed
in the company’s most recent annual report on Form 10-K and
reports on Form 10-Q and Form 8-K. These documents are
available from the SEC, the Bristol-Myers Squibb website or
from Bristol-Myers Squibb Investor Relations.
In addition, any forward-looking statements represent our
estimates only as of today and should not be relied upon as
representing our estimates as of any subsequent date. While
we may elect to update forward-looking statements at some
point in the future, we specifically disclaim any obligation to do
so, even if our estimates change.
NOT FOR PRODUCT PROMOTIONAL USE 2

3. Data as of December 31, 2011
NME Development Portfolio
Exploratory Development * Full Marketed Product
Development ^ Development †
EGFR/IGFR NS5A Second
Tandem Adnectin PEG-FGF21 LXR Modulators Generation Brivanib YERVOYTM NULOJIX ®
Pegdinetanib 11βHSD NS5B Site 1
(VEGF R-2 Adnectin)
PCSK9 Adnectin Inhibitor SPRYCEL® ELIQUISTM **
Inhibitors Necitumumab
CCR2 / 5 α-7 Nicotinic
Anti-CD70 ADC TGR5 Agonist Antagonists Agonist ERBITUX® BARACLUDE®
Elotuzumab
JAK2 Inhibitor FGF21-PKE IKACh Inhibitors Aβ Modulator
IXEMPRA® REYATAZ®
Adnectin
Triple Reuptake
IGF-1R
IKur Antagonists Inhibitors
Dapagliflozin SUSTIVA® /
Antagonist GPR119 Agonists ORENCIA® ATRIPLA®
Microtubule
CCR1 Peginterferon ONGLYZA ® /
SMO Antagonist Stabilizer Daclatasvir ABILIFY®
Antagonists lambda-1a (NS5A Inhibitor) KOMBIGLYZETM XR
Avagacestat
Asunaprevir (Gamma Secretase
IL-21 Anti-IP10 (NS3 Inhibitor) Inhibitor)
Anti-KIR NS5B Inhibitor GABA/Nicotinic
Anti-CD28 Modulator
Urelumab HIV Attachment
Anti-IL6 Inhibitor CGRP Antagonist
(Anti-CD137)
Notch Inhibitors IL-23 Adnectin Anti-PD-L1
Anti-PD1 Anti-IL31 NRT Inhibitor
HIV Maturation
Anti-CXCR4 Anti-CD40L Inhibitor
* Post discovery through Phase II
NS5B Primer Grip ^ Registrational program
Anti-LAG3 LPA1 Antagonist Inhibitor
† Approved in at least one major market
ONC MET IMM CV VIR NS **ELIQUIS is approved for VTE Prevention in the EU
NOT FOR PRODUCT PROMOTIONAL USE 3

4. HCV – Area of High Unmet Need
Historic Standard of Current Standard of BMS Goal
Care Care
(<50% Cure Rates) (<80% Cure Rates)
Higher Cure Rates
Through:
PEG-IFN-α
PEG-IFN-α + • Improved efficacy
+ Ribavirin
Ribavirin + • Improved safety /
1st Wave PI tolerability
• Reduced duration of
treatment
NOT FOR PRODUCT PROMOTIONAL USE

5. BMS Well Positioned With Broad HCV Portfolio
 Daclatasvir (DAC): Potential 1st in class, differentiated NS5A
Inhibitor in Ph III
 -189: Potent, pan-genotypic Nuc through acquisition of Inhibitex
 Asunaprevir (ASV): Protease Inhibitor in Ph III combo with DAC
 NS5B non-Nuc (BMS-791325) in development in combo with DAC
and ASV
 Peg-IFN Lambda in development for HCV and HBV
 Strategic partnerships to complement our internal portfolio
NOT FOR PRODUCT PROMOTIONAL USE 5

6. Daclatasvir Phase III Program
 DAC+ ASV (Dual) in GT1b patients in Japan
– Enrollment complete, expect trial completion in 2013
– ~ 2M HCV patients in Japan with about 70% GT1b
 DAC + ASV (Dual) in US and EU
– GT1b – naives, alfa ineligible / intolerants, alfa null / partials
– Expected to initiate in 2012
 DAC + ASV + P/R (Quad) in US and EU
– GT1 null responders
– Expected to initiate in 2012
 DAC + P/R in co-infected and minority populations
– Studies ongoing
NOT FOR PRODUCT PROMOTIONAL USE 6

7. -189: A Key Component of Our HCV Portfolio
 Confident in having dose that provides sufficient viral suppression
and resistance coverage with acceptable safety and tolerability
 Development Plan
– Ph II -189 + DAC +/- RBV – Expected to start in 2012, Ph III in 2013
– Ph II -189 + P/R in GT2/3 – Ongoing
• Plan to expand to include combinations of 189, DAC and RBV
 -189 is a potent, pan-genotypic Nuc
– 7 day study in GT1 patients
• >4 log drop in viral load at 200mg QD
• Close to 4 log drop at 100mg QD + RBV
NOT FOR PRODUCT PROMOTIONAL USE 7

8. BofA
Health Care Conference
Doug Manion
Senior Vice President, Development
Virology, Neuroscience and Japan
May 17, 2012
8